ARTICLE | Regulation
Preference pioneers
How Rituxan Hycela became the first drug with patient preference data on its U.S. label
December 22, 2017 11:39 PM UTC
Rituxan Hycela subcutaneous rituximab provides the first example of how companies can get patient preference data on an FDA-approved drug label.
The new formulation is intended to reduce the treatment burden of rituximab therapy, which was previously available only as an IV infusion that took 1.5-6 hours. The subcutaneous formulation can be administered by a healthcare professional in 5-7 minutes. ...